The company claims about natural GLP-1 support represent their marketing positioning and have not been evaluated by the FDA as finished products
Retatrutide is used in preclinical models to explore how coordinated receptor activation can impact glucose metabolism, lipid accumulation, appetite regulation, and systemic energy regulation
For MASH and liver disease Survodutide has Phase 2 data published in the NEJM showing 62% MASH resolution at the 4.8 mg dose, 62% liver fat reduction at the 6.0 mg dose, and meaningful fibrosis improvement
NAD+ is essential to cellular function and by default, the creation of energy
Lifestyle modifications We urge you to focus on sustainable lifestyle changes rather than short-term solutions
Data suggest that activation of GIP-R decreases inflammation in adipose tissue and cytokines levels (such as IL-6) and promotes the rise of serum adiponectin levels, a cytokine with anti-inflammatory effects and beneficial effects on diabetic nephropathy, which can explain potential beneficial effects on kidneys (even if GIP-R are not present) (47)